Various methods and systems are provided for longitudinal presentation of patient information. In one example, a computing device comprises a display screen, the computing device being configured to display on the screen a timeline of patient medical information including a plurality of symbols representing the patient medical information, wherein a symbol of the plurality of symbols is selectable to launch a details panel and enable a report that references the displayed patient medical information to be seen within the timeline, and wherein the symbol is displayed while the details panel is in an un-launched state.

Various methods and systems are provided for longitudinal presentation of patient information. In one example, a computing device comprises a display screen, the computing device being configured to display on the screen a timeline of patient medical information including a plurality of symbols representing the patient medical information, wherein a symbol of the plurality of symbols is selectable to launch a details panel and enable a report that references the displayed patient medical information to be seen within the timeline, and wherein the symbol is displayed while the details panel is in an un-launched state.

A method is provided for lowering blood pressure in a subject in need thereof by administering a dihydropyridine-type calcium channel blocker pharmaceutical composition to a subject qualified for over-the-counter access to the dihydropyridine-type calcium channel blocker pharmaceutical composition. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes isradipine, nifedipine, or nisoldipine. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate or a pharmaceutically acceptable salt thereof.

A method is provided for lowering blood pressure in a subject in need thereof by administering a dihydropyridine-type calcium channel blocker pharmaceutical composition to a subject qualified for over-the-counter access to the dihydropyridine-type calcium channel blocker pharmaceutical composition. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes isradipine, nifedipine, or nisoldipine. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate or a pharmaceutically acceptable salt thereof.

Method and system for providing basal profile modification in insulin therapy for use with infusion devices includes periodically monitoring the analyte levels of a patient for a predetermined period of time in order to determine, based on the monitored analyte levels, an appropriate modification factor to be incorporated into the underlying basal profile which was running at the time the periodic monitoring of the analyte levels were performed.

Method and system for providing basal profile modification in insulin therapy for use with infusion devices includes periodically monitoring the analyte levels of a patient for a predetermined period of time in order to determine, based on the monitored analyte levels, an appropriate modification factor to be incorporated into the underlying basal profile which was running at the time the periodic monitoring of the analyte levels were performed.

A system for assessing risks of T2DM complications includes: a data acquisition module obtaining and inputting assessment parameters of a patient with T2DM into a risk assessment module; and the risk assessment module inputting the assessment parameters into a number of risk equations and using it to calculate risk values of the complication occurring after a period of time. The risk equation for all diabetic complications (i,j) is:

r.sub.a(t,i,j)=1−exp{[H(t.sub.0)−H(t.sub.1)]C.sub.a(t,i,j)}

r.sub.a(t, i, j) is the risk value for the patient to develop the complication j from the current disease i at age t. t.sub.0 is an age of one patient at a state of the disease i. t.sub.1 is an age of the patient after the period of time. t is an age between t.sub.0 and t.sub.1. H(t.sub.0) and H(t.sub.1) are hazards of the complication occurring at the age t.sub.0 and the age t.sub.1, respectively. C.sub.a(t, i, j) is a Cox proportional hazards regression expression, and is represented by:

C.sub.a(t,i,j)=exp(R.sub.a(t,i,j))

R.sub.a(t, i, j) is an influence degree of risk factors X on the complication j.

A system for assessing risks of T2DM complications includes: a data acquisition module obtaining and inputting assessment parameters of a patient with T2DM into a risk assessment module; and the risk assessment module inputting the assessment parameters into a number of risk equations and using it to calculate risk values of the complication occurring after a period of time. The risk equation for all diabetic complications (i,j) is:

r.sub.a(t,i,j)=1−exp{[H(t.sub.0)−H(t.sub.1)]C.sub.a(t,i,j)}

r.sub.a(t, i, j) is the risk value for the patient to develop the complication j from the current disease i at age t. t.sub.0 is an age of one patient at a state of the disease i. t.sub.1 is an age of the patient after the period of time. t is an age between t.sub.0 and t.sub.1. H(t.sub.0) and H(t.sub.1) are hazards of the complication occurring at the age t.sub.0 and the age t.sub.1, respectively. C.sub.a(t, i, j) is a Cox proportional hazards regression expression, and is represented by:

C.sub.a(t,i,j)=exp(R.sub.a(t,i,j))

R.sub.a(t, i, j) is an influence degree of risk factors X on the complication j.

An example of a system for review of clinical data includes a medical device configured to receive patient data signals from patient interface devices coupled to the medical device, and an auxiliary device configured to communicatively couple to the medical device via a communication channel and including an output device, a memory, a communication interface, and a processor configured to establish the communication channel, estimate a transmission age for the patient data, receive the patient data from the medical device via the communication channel, determine a patient data age based on at least one of the transmission age and a playback selection age, select a patient data age threshold based on a patient data context, compare the patient data age to the patient data age threshold to determine a patient data age indication, and provide the patient data and the patient data age indication at the output device.

An example of a system for review of clinical data includes a medical device configured to receive patient data signals from patient interface devices coupled to the medical device, and an auxiliary device configured to communicatively couple to the medical device via a communication channel and including an output device, a memory, a communication interface, and a processor configured to establish the communication channel, estimate a transmission age for the patient data, receive the patient data from the medical device via the communication channel, determine a patient data age based on at least one of the transmission age and a playback selection age, select a patient data age threshold based on a patient data context, compare the patient data age to the patient data age threshold to determine a patient data age indication, and provide the patient data and the patient data age indication at the output device.